Lista de obras -

Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study.

artículo científico publicado en 2008

Characterization of the Cross-Neutralizing Antibody Response Against Hepatitis C Virus in the Liver Transplantation Setting ⬇️

artículo científico publicado el 14 de marzo de 2011

Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies

article

Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants.

artículo científico publicado en 2017

Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors

artículo científico publicado en 2017

Efficient infectious cell culture systems of the hepatitis C virus (HCV) prototype strains HCV-1 and H77.

artículo científico publicado en 2014

Evolution of the NS3 and NS5B regions of the hepatitis C virus during disease recurrence after liver transplantation.

artículo científico publicado en 2007

Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.

artículo científico publicado en 2016

Hepatitis C virus compartmentalization and infection recurrence after liver transplantation.

artículo científico publicado en 2009

Hepatitis C virus superinfection of liver grafts: a detailed analysis of early exclusion of non-dominant virus strains.

artículo científico publicado en 2010

Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus

artículo científico publicado en 2013

Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations.